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Stent malposition, recognized as an entity with the advent of intravascular imaging, refers to the lack of full contact between stent struts and the vessel wall after percutaneous coronary intervention ([Figure](#jah34005-fig-0001){ref-type="fig"}). Malapposition may be present immediately after placement of stents (acute stent malapposition), or it may develop later (late stent malapposition), which can, in turn, be categorized as late persistent malapposition (ongoing since the time of implantation) or late acquired malapposition (developing de novo during follow‐up).[1](#jah34005-bib-0001){ref-type="ref"}

![Intravascular imaging assessment of malapposition. **A**, Optical coherence tomography (OCT) automated detection of malapposition. The high resolution of OCT allows automatic detection of malapposition. Malapposed segments and stent struts are highlighted in red in the angiographic coregistration (i), OCT cross‐section (ii), automated measures apposition bar (white arrowheads: red segments of white bar denote malapposed segments) (iii), and rendered stent (red arrowheads: red stent struts of white rendered stent denote malapposed segments) in longitudinal OCT image (iv). **B**, OCT cross‐section showing acute malapposition (white arrowheads). **C**, OCT cross‐section showing neointimal growth toward malapposed struts 15 months after drug‐eluting stent implantation. Intravascular ultrasound (**D**) and OCT (**E**) coregistered cross‐sections from the same patient, showing malapposition (white arrowheads) much more easily visible by OCT because of its superior resolution. AS indicates area stenosis; MLA, minimum lumen area.](JAH3-8-e012262-g001){#jah34005-fig-0001}

Acute stent malapposition occurs because of a mismatch between the stent and vessel lumen contours, and it can be the result of suboptimal stent deployment (stent undersizing or stent underexpansion) or secondary to vessel architecture/lesion characteristics (eg, occurring at bifurcation points, in large vessels, in long lesions requiring multiple overlapping stents, or secondary to stent struts interacting with an eccentric calcific plaque).[1](#jah34005-bib-0001){ref-type="ref"}, [2](#jah34005-bib-0002){ref-type="ref"} Design and alloy of the stent metal could also affect stent conformability to plaque and vessel irregularities and determine the degree of acute stent malapposition.[3](#jah34005-bib-0003){ref-type="ref"}

Acute stent malapposition is a common finding after implantation of drug‐eluting stents (DESs), observed, on average, in 15% of stents by intravascular ultrasound (IVUS)[4](#jah34005-bib-0004){ref-type="ref"} and at a higher rate of 50% by optical coherence tomography (OCT),[5](#jah34005-bib-0005){ref-type="ref"} because of the higher resolution of OCT compared with IVUS and the ability for automatic detection of malapposed struts ([Figure](#jah34005-fig-0001){ref-type="fig"}). As shown in serial OCT studies, acute stent malapposition may be corrected by vascular remodeling, resulting in complete neointimal integration during the follow‐up period (especially in malapposed struts with a distance to intimal surface of \<0.35 mm).[6](#jah34005-bib-0006){ref-type="ref"} However, incomplete strut apposition may persist, leading to late persistent malapposition. In contrast, late acquired malapposition may result from positive (outward) remodeling causing an increase in vessel dimensions greater than abluminal tissue growth (responsible for approximately one third of late acquired malapposition[7](#jah34005-bib-0007){ref-type="ref"}) or from abluminal thrombus dissolution after primary percutaneous coronary intervention or plaque regression without positive remodeling over time.[8](#jah34005-bib-0008){ref-type="ref"}

Although intravascular imaging studies have established stent underexpansion as one of the most important independent predictors of stent‐related outcomes,[9](#jah34005-bib-0009){ref-type="ref"} the potential impact of acute stent malapposition on stent failure rates (ie, in‐stent restenosis and stent thrombosis) has been a matter of controversy.[8](#jah34005-bib-0008){ref-type="ref"} Bench‐top in vitro experiments,[10](#jah34005-bib-0010){ref-type="ref"} pathophysiological examinations,[11](#jah34005-bib-0011){ref-type="ref"} and small serial IVUS and OCT studies[12](#jah34005-bib-0012){ref-type="ref"} have supported the theoretical link between exposed, uncovered malapposed struts and increased propensity for local thrombus formation, possibly through causing local flow disturbances and delayed healing; however, several larger studies using IVUS[4](#jah34005-bib-0004){ref-type="ref"}, [13](#jah34005-bib-0013){ref-type="ref"} or OCT[1](#jah34005-bib-0001){ref-type="ref"}, [9](#jah34005-bib-0009){ref-type="ref"} have shown no relationship between acute stent malapposition and early, late, or very late stent thrombosis after DES implantation (a finding that is perhaps not surprising given the almost ubiquitous presence of a degree of malapposition on poststenting OCT). Moreover, no significant relationship has been established between the extent of acute stent malapposition and adverse clinical outcomes.[2](#jah34005-bib-0002){ref-type="ref"}, [4](#jah34005-bib-0004){ref-type="ref"} Indeed, in the IVUS substudy of the ADAPT‐DES (Assessment of Dual Antiplatelet Therapy With Drug‐Eluting Stents) study, the largest areas of stent malposition were observed in the group of patients with no major adverse cardiovascular events during the follow‐up.[4](#jah34005-bib-0004){ref-type="ref"}

Late stent malapposition is a frequent finding in association with very late DES thrombosis,[14](#jah34005-bib-0014){ref-type="ref"} which may suggest a potential causal relationship between late malapposition and very late DES. However, this cause‐and‐effect relationship has been challenged[8](#jah34005-bib-0008){ref-type="ref"} by studies relating late stent malapposition, very late stent thrombosis, and inflammation[15](#jah34005-bib-0015){ref-type="ref"}; studies reporting a high prevalence of strut fracture in very late stent thrombosis[16](#jah34005-bib-0016){ref-type="ref"}; and OCT‐based studies indicating that neoatherosclerosis may be a more important cause of very late stent thrombosis than late stent malapposition.[17](#jah34005-bib-0017){ref-type="ref"} Nonetheless, the cumulative data on the safety of malapposition in metallic DES cannot be extrapolated to bioresorbable scaffolds because of differences in the design, composition, and biodegradation of the scaffolds.

One of the major limitations of the current data examining the clinical relevance and potential impact of different types of malapposition is the paucity of OCT‐based studies from large registries that do the following: (1) compare serial OCT images with paired OCT images that are acquired immediately after stent implantation; and (2) include careful, systematic, long‐term clinical follow‐up. In this issue of the *Journal of the American Heart Association* (*JAHA*), Im et al seek to address this inadequacy by reporting the long‐term clinical outcomes (\>5 years compared with 2 years of follow‐up on the previous report from the same cohort) in 351 patients with 356 lesions.[18](#jah34005-bib-0018){ref-type="ref"} Postprocedural OCT images were analyzed in conjunction with subsequent OCT images that were acquired within 1 year (175±60 days) after stent implantation. Consistent with previous studies,[1](#jah34005-bib-0001){ref-type="ref"}, [2](#jah34005-bib-0002){ref-type="ref"}, [3](#jah34005-bib-0003){ref-type="ref"} late stent malapposition was detected in stents deployed in calcified lesions, in larger‐vessel diameters, or in more severely stenotic lesions compared with stents without malapposed struts.

The most important finding of the study was that the cumulative 8‐year rate of composite cardiovascular events (cardiovascular death, target lesion‐ and target vessel‐related nonfatal myocardial infarction, target lesion and target vessel revascularization, and stent thrombosis) in patients with late stent malapposition was not significantly different from that in patients without late stent malapposition (7.3% versus 10.5%; *P*=0.822), a finding that is in agreement with accumulated evidence from multiple previous studies[1](#jah34005-bib-0001){ref-type="ref"}, [2](#jah34005-bib-0002){ref-type="ref"}, [4](#jah34005-bib-0004){ref-type="ref"}, [5](#jah34005-bib-0005){ref-type="ref"}, [7](#jah34005-bib-0007){ref-type="ref"}, [9](#jah34005-bib-0009){ref-type="ref"}, [13](#jah34005-bib-0013){ref-type="ref"}, [19](#jah34005-bib-0019){ref-type="ref"}, [20](#jah34005-bib-0020){ref-type="ref"}, [21](#jah34005-bib-0021){ref-type="ref"} ([Table](#jah34005-tbl-0001){ref-type="table"}). Similarly, the clinical events were not different in subgroups on the basis of the type of late stent malapposition (ie, late persistent, late acquired, or a combination of the 2 versus no late stent malapposition) nor were they different between the first‐ and second‐generation DESs. Furthermore, there was no difference in clinical outcomes on the basis of cross‐sectional malapposition distance (≥400 versus \<400 μm; *P*=0.87) or longitudinal length of strut malapposition (≥1 versus \<1 mm; *P*=0.98).

###### 

IVUS and OCT Studies Correlating Stent Malapposition With Clinical Outcomes

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                        MISSION Intervention            Imaging Modality   Patients (Lesions)   Clinical Follow‐Up, mo   Outcome                                                                 *P* Value        
  -------------------------------------------------------------- ------------------------------- ------------------ -------------------- ------------------------ ----------------------------------------------------------------------- ---------------- -------
  Van der Hoeven et al[19](#jah34005-bib-0019){ref-type="ref"}   MISSION Intervention            IVUS               184                  12                       0% ST                                                                   0% ST            NS

  Guo et al[7](#jah34005-bib-0007){ref-type="ref"}               HORIZONS‐AMI                    IVUS               241 (263)            12                       0% Death or ST                                                          0% Death or ST   NS

  Steinberg et al[13](#jah34005-bib-0013){ref-type="ref"}        TAXUS IV, V, and VI and ATLAS   IVUS               1580                 9\                       11.6% MACEs\                                                            8.8% MACEs\      0.45\
                                                                                                                                         24                       LASM: 8.3% MACEs                                                        8.1% MACEs       0.87

  Wang et al[4](#jah34005-bib-0004){ref-type="ref"}              ADAPT‐DES                       IVUS               2072 (2446)          24                       5.2% MACEs                                                              4.5% MACEs       0.58

  Im et al[1](#jah34005-bib-0001){ref-type="ref"}                                                OCT                351 (356)            24                       LPSM vs LASM vs LPSM and LASM: 2.2%, 3.2%, and 0% MACEs, respectively   3.2% MACEs       1.0

  Soeda et al[20](#jah34005-bib-0020){ref-type="ref"}            MGH OCT registry                OCT                786 (900)            12                       1.7% DoCE                                                               2.9% DoCE        NS

  Prati et al[5](#jah34005-bib-0005){ref-type="ref"}             CLI‐OPCI II                     OCT                832 (1002)           12                       MACE HR: 1.15 (95% CI: 0.8--1.7)                                                         0.52

  Prati et al[21](#jah34005-bib-0021){ref-type="ref"}            CLI‐OPCI ACS                    OCT                507 (588)            12                       MACE HR: 0.84 (95% CI: 0.5--1.5)                                                         0.57

  Romagnoli et al[2](#jah34005-bib-0002){ref-type="ref"}         CLI‐OPCI registry               OCT                864 (1020)           24                       MACE HR: 0.79 (95% CI: 0.5--1.2)                                                         0.26

  Prati et al[9](#jah34005-bib-0009){ref-type="ref"}             CLI‐OPCI LATE                   OCT                1211                 36                       DoCE HR: 0.92 (95% CI: 0.7--1.2)                                                         0.56

  Im et al[18](#jah34005-bib-0018){ref-type="ref"}                                               OCT                351 (356)            96                       LSM: 7.3% MACEs;\                                                       10.5% MACEs\     0.82\
                                                                                                                                                                  LPSM vs LASM vs LPSM and LASM: 9.6%, 9.7%, and 0% MACEs, respectively   10.5% MACEs      0.47
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADAPT‐DES indicates Assessment of Dual Antiplatelet Therapy With Drug‐Eluting Stents; CLI‐OPCI ACS, Centro per la Lotta contro l'Infarto‐Optimization of Percutaneous Coronary Intervention Acute coronary Syndrome; CLI‐OPCI LATE, Centro per la Lotta contro l'Infarto‐Optimization of Percutaneous Coronary Intervention Late; CLI‐OPCI, Centro per la Lotta contro l\'Infarto--Optimization of Percutaneous Coronary Intervention II; DoCE, device‐oriented cardiovascular event; HORIZON S‐AMI, Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction; HR, hazard ratio; IVUS, intravascular ultrasound; LASM, late acquired stent malapposition; LPSM, late persistent stent malapposition; LSM, late stent malapposition; MACE, major adverse cardiovascular event; MGH OCT registry: Massachusetes General hospital Optical Coherence tomography registry; MISSION Intervention: A Prospective Randomised Controlled Trial to Evaluate the Efficacy of Drug‐Eluting Stents Versus Bare‐Metal Stents for the Treatment of Acute Myocardial Infarction; NS, nonsignificant; OCT, optical coherence tomography; ST, stent thrombosis; TAXUS ATLAS, Polymer‐Based, Paclitaxel‐Eluting TAXUS Liberté Stent in De Novo Lesions.

Indicates acute stent malapposition, unless otherwise specified.
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Despite several limitations of the study by Im et al,[18](#jah34005-bib-0018){ref-type="ref"} including the single‐center, nonrandomized, cross‐sectional design, with patients arbitrarily included in the analysis on the basis of the performance of 2 serial OCTs, among others, it provides the longest follow‐up data to date correlating OCT‐detected stent malapposition with clinical outcomes. The results build on concordant findings at the 2‐year follow‐up point in the same cohort of patients[1](#jah34005-bib-0001){ref-type="ref"} and are in agreement with 2 recent analyses from the large, multicenter, OCT‐based registry, CLI‐OPCI (Centro per la Lotta contro l\'Infarto--Optimization of Percutaneous Coronary Intervention),[2](#jah34005-bib-0002){ref-type="ref"}, [9](#jah34005-bib-0009){ref-type="ref"} including the CLI‐OPCI LATE (Centro per la Lotta contro l\'Infarto‐Optimization of Percutaneous Coronary Intervention Late) study that enrolled ≈1200 patients with a median follow‐up of ≈3 years; in this study, acute stent malapposition (detected in ≈50% of stents) was not significantly related to the risk of long‐term stent failure (hazard ratio, 0.92).[9](#jah34005-bib-0009){ref-type="ref"}

In conclusion, the study by Im et al[18](#jah34005-bib-0018){ref-type="ref"} adds long‐term data on the safety and lack of discernible clinical sequelae of different types of OCT‐detected stent malapposition. Until data are available to the contrary, the emphasis on correcting acute stent malapposition may not be based on current evidence and should be replaced with more attention paid to what is known to be important in optimizing stent‐related outcomes (ie, stent expansion and adequate lesion coverage).
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